|
1
|
Kolenda T, Białas P, Guglas K, Stasiak M, Kozłowska-Masłoń J, Tylkowska K, Zapłata A, Poter P, Janiczek-Polewska M, Mantaj P, Gieremek P, Kazimierczak U, Przybyła A, Regulska K, Stanisz B, Leporowska E, Mackiewicz A, Mackiewicz J, Kazmierska J, Cybulski Z, Teresiak A. lncRNA EGOT Is the Marker of HPV Infection and a Prognostic Factor for HNSCC Patients. Biomedicines 2025; 13:798. [PMID: 40299341 PMCID: PMC12025276 DOI: 10.3390/biomedicines13040798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2025] [Revised: 03/02/2025] [Accepted: 03/11/2025] [Indexed: 04/30/2025] Open
Abstract
Background: High-risk human papillomavirus (HPV) contributes to oropharyngeal cancers through mechanisms involving the deregulation of host cell functions by oncoproteins E6 and E7. Changes in the epigenome, particularly involving long non-coding RNAs (lncRNAs), are crucial for understanding HPV-related carcinogenesis. Methods: This study aimed to analyze the expression levels of lncRNAs in HPV-related head and neck squamous cell carcinoma (HNSCC) to determine their biological and clinical significance, addressing the current gap in clinically validated biomarkers for early screening and therapeutic interventions. Results: The study highlights the significant overexpression of the EGOT gene in HPV-positive HNSCC samples, suggesting its potential as a marker to distinguish between HPV-negative and HPV-positive cases. Furthermore, high EGOT expression correlates with better overall survival (OS) and indicates possible resistance to therapy, making it a valuable prognostic factor. Conclusions: These findings underscore the potential of incorporating EGOT expression analysis in clinical practice for improved patient stratification and treatment outcomes in HNSCC.
Collapse
Affiliation(s)
- Tomasz Kolenda
- Research and Implementation Unit, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznan, Poland; (K.G.); (K.R.); (Z.C.); (A.T.)
- Microbiology Laboratory, Greater Poland Cancer Centre, Garbary Street 15, 61-866 Poznan, Poland;
- Department of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, 8 Rokietnicka Street, 60-806 Poznan, Poland; (M.S.); (U.K.); (A.M.)
- Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 15 Garbary Street, 61-866 Poznan, Poland
| | - Piotr Białas
- Department of Cell Biology, Poznan University of Medical Sciences, 5D Rokietnicka, 60-806 Poznan, Poland
| | - Kacper Guglas
- Research and Implementation Unit, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznan, Poland; (K.G.); (K.R.); (Z.C.); (A.T.)
- Microbiology Laboratory, Greater Poland Cancer Centre, Garbary Street 15, 61-866 Poznan, Poland;
| | - Maciej Stasiak
- Department of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, 8 Rokietnicka Street, 60-806 Poznan, Poland; (M.S.); (U.K.); (A.M.)
- Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 15 Garbary Street, 61-866 Poznan, Poland
| | - Joanna Kozłowska-Masłoń
- Laboratory of Cancer Genetics, Greater Poland Cancer Centre, 15 Garbary Street, 61-866 Poznan, Poland;
- Faculty of Biology, Institute of Human Biology and Evolution, Adam Mickiewicz University, Uniwersytetu Poznańskiego 6, 61-614 Poznan, Poland
| | - Karina Tylkowska
- Microbiology Laboratory, Greater Poland Cancer Centre, Garbary Street 15, 61-866 Poznan, Poland;
- Faculty of Biology, Adam Mickiewicz University, Umultowska 89, 61-614 Poznan, Poland
| | - Anna Zapłata
- Department of Laboratory Diagnostics, Greater Poland Cancer Centre, 15 Garbary Street, 61-866 Poznan, Poland; (A.Z.); (E.L.)
| | - Paulina Poter
- Department of Oncologic Pathology and Prophylaxis, Poznan University of Medical Sciences, Greater Poland Cancer Center, 15 Garbary Street, 61-866 Poznan, Poland;
| | - Marlena Janiczek-Polewska
- Department of Clinical Oncology, Greater Poland Cancer Centre, 15 Garbary Street, 61-866 Poznan, Poland;
- Department of Electroradiology, Poznan University of Medical Sciences, 61-701 Poznan, Poland
| | - Patrycja Mantaj
- Radiation Protection Department, Greater Poland Cancer Centre, 15 Garbary Street, 61-866 Poznan, Poland;
| | - Paulina Gieremek
- Departament of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Rokietnicka Street 3, 60-806 Poznan, Poland; (P.G.); (B.S.)
- Pharmacy, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznan, Poland
| | - Urszula Kazimierczak
- Department of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, 8 Rokietnicka Street, 60-806 Poznan, Poland; (M.S.); (U.K.); (A.M.)
- Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 15 Garbary Street, 61-866 Poznan, Poland
| | - Anna Przybyła
- Department of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, 8 Rokietnicka Street, 60-806 Poznan, Poland; (M.S.); (U.K.); (A.M.)
| | - Katarzyna Regulska
- Research and Implementation Unit, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznan, Poland; (K.G.); (K.R.); (Z.C.); (A.T.)
- Pharmacy, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznan, Poland
| | - Beata Stanisz
- Departament of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Rokietnicka Street 3, 60-806 Poznan, Poland; (P.G.); (B.S.)
| | - Ewa Leporowska
- Department of Laboratory Diagnostics, Greater Poland Cancer Centre, 15 Garbary Street, 61-866 Poznan, Poland; (A.Z.); (E.L.)
| | - Andrzej Mackiewicz
- Department of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, 8 Rokietnicka Street, 60-806 Poznan, Poland; (M.S.); (U.K.); (A.M.)
- Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 15 Garbary Street, 61-866 Poznan, Poland
| | - Jacek Mackiewicz
- Department of Medical and Experimental Oncology, Institute of Oncology, Poznan University of Medical Sciences, 60-512 Poznan, Poland;
| | - Joanna Kazmierska
- Radiotherapy Department II, Greater Poland Cancer Centre, 15 Garbary Street, 61-866 Poznan, Poland;
| | - Zefiryn Cybulski
- Research and Implementation Unit, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznan, Poland; (K.G.); (K.R.); (Z.C.); (A.T.)
- Microbiology Laboratory, Greater Poland Cancer Centre, Garbary Street 15, 61-866 Poznan, Poland;
| | - Anna Teresiak
- Research and Implementation Unit, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznan, Poland; (K.G.); (K.R.); (Z.C.); (A.T.)
- Laboratory of Cancer Genetics, Greater Poland Cancer Centre, 15 Garbary Street, 61-866 Poznan, Poland;
| |
Collapse
|
|
2
|
Zolfi E, Khaleghi Mehr F, Emtiazi N, Moradi Y. A review of the carcinogenic potential of human papillomavirus (HPV) in urological cancers. Virol J 2025; 22:53. [PMID: 40022189 PMCID: PMC11871667 DOI: 10.1186/s12985-025-02682-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2024] [Accepted: 02/24/2025] [Indexed: 03/03/2025] Open
Abstract
Direct skin-to-skin contact during intimate sexual contact with a human papillomavirus (HPV)-positive individual is often the cause of HPV infection. In addition, many studies have been written up to date that look at the role of HPV in the growth of other types of tumors. Not all urological cancers are associated with HPV. However, penile cancer (PC) is often caused by HPV, especially high-risk types. HPV-16 has been the most frequent (68.3%), followed by HPV-6 (8.1%) and HPV-18 (6.9%). An increased risk of getting certain types of urinary cancers like prostate, bladder, testicular, and kidney has also been linked to these infections. Additionally, HPV may play a part in continuous inflammation and cancer progression in different organs and tissues. So, making HPV vaccine programs available to more people of the male sex around the world could significantly lower the number of urinary cancers caused by HPV. The critical effects of HPV on different types of urologic cancers (UCs), such as testicular, prostate, penile, and kidney cancer, and the importance of HPV vaccination have been seen in this study.
Collapse
Affiliation(s)
- Ehsan Zolfi
- Department of Urology, School of Medicine, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran
| | - Farhood Khaleghi Mehr
- Department of Urology, School of Medicine, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran
| | - Nikoo Emtiazi
- Department of Pathology Medicine, Rasool Akram Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
| | - Yasaman Moradi
- Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
|
3
|
Mobaraki G, Shi S, Liu D, Smits KM, Severens K, Lommen K, Rennspiess D, Speel EJM, Winnepenninckx V, Klufah F, Samarska I, zur Hausen A. Mapping of Human Polyomavirus in Renal Cell Carcinoma Tissues. Int J Mol Sci 2024; 25:8213. [PMID: 39125783 PMCID: PMC11312419 DOI: 10.3390/ijms25158213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2024] [Revised: 07/18/2024] [Accepted: 07/23/2024] [Indexed: 08/12/2024] Open
Abstract
Worldwide, the incidence of renal cell carcinoma (RCC) is rising, accounting for approximately 2% of all cancer diagnoses and deaths. The etiology of RCC is still obscure. Here, we assessed the presence of HPyVs in paraffin-embedded tissue (FFPE) resected tissue from patients with RCC by using different molecular techniques. Fifty-five FFPE tissues from 11 RCC patients were included in this study. Consensus and HPyV-specific primers were used to screen for HPyVs. Both PCR approaches revealed that HPyV is frequently detected in the tissues of RCC kidney resections. A total of 78% (43/55) of the tissues tested were positive for at least one HPyV (i.e., MCPyV, HPyV6, HPyV7, BKPyV, JCPyV, or WUyV). Additionally, 25 tissues (45%) were positive for only one HPyV, 14 (25%) for two HPyVs, 3 (5%) for three HPyVs, and 1 one (1%) tissue specimen was positive for four HPyVs. Eleven (20%) RCC specimens were completely devoid of HPyV sequences. MCPyV was found in 24/55 RCC tissues, HPyV7 in 19, and HPyV6 in 8. The presence of MCPyV and HPyV6 was confirmed by specific FISH or RNA-ISH. In addition, we aimed to confirm HPyV gene expression by IHC. Our results strongly indicate that these HPyVs infect RCC and nontumor tissues, possibly indicating that kidney tissues serve as a reservoir for HPyV latency. Whether HPyVs possibly contribute to the etiopathogenesis of RCC remains to be elucidated.
Collapse
Affiliation(s)
- Ghalib Mobaraki
- Department of Pathology, GROW-Research Institute for Oncology & Reproduction, Maastricht University, Medical Centre+, 6229 HX Maastricht, The Netherlands; (G.M.); (S.S.); (D.L.); (K.M.S.); (K.S.); (K.L.); (D.R.); (E.-J.M.S.); (V.W.); (F.K.); (I.S.)
- Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Jazan University, Jazan 45142, Saudi Arabia
| | - Shuai Shi
- Department of Pathology, GROW-Research Institute for Oncology & Reproduction, Maastricht University, Medical Centre+, 6229 HX Maastricht, The Netherlands; (G.M.); (S.S.); (D.L.); (K.M.S.); (K.S.); (K.L.); (D.R.); (E.-J.M.S.); (V.W.); (F.K.); (I.S.)
| | - Dan Liu
- Department of Pathology, GROW-Research Institute for Oncology & Reproduction, Maastricht University, Medical Centre+, 6229 HX Maastricht, The Netherlands; (G.M.); (S.S.); (D.L.); (K.M.S.); (K.S.); (K.L.); (D.R.); (E.-J.M.S.); (V.W.); (F.K.); (I.S.)
| | - Kim M. Smits
- Department of Pathology, GROW-Research Institute for Oncology & Reproduction, Maastricht University, Medical Centre+, 6229 HX Maastricht, The Netherlands; (G.M.); (S.S.); (D.L.); (K.M.S.); (K.S.); (K.L.); (D.R.); (E.-J.M.S.); (V.W.); (F.K.); (I.S.)
| | - Kim Severens
- Department of Pathology, GROW-Research Institute for Oncology & Reproduction, Maastricht University, Medical Centre+, 6229 HX Maastricht, The Netherlands; (G.M.); (S.S.); (D.L.); (K.M.S.); (K.S.); (K.L.); (D.R.); (E.-J.M.S.); (V.W.); (F.K.); (I.S.)
| | - Kim Lommen
- Department of Pathology, GROW-Research Institute for Oncology & Reproduction, Maastricht University, Medical Centre+, 6229 HX Maastricht, The Netherlands; (G.M.); (S.S.); (D.L.); (K.M.S.); (K.S.); (K.L.); (D.R.); (E.-J.M.S.); (V.W.); (F.K.); (I.S.)
| | - Dorit Rennspiess
- Department of Pathology, GROW-Research Institute for Oncology & Reproduction, Maastricht University, Medical Centre+, 6229 HX Maastricht, The Netherlands; (G.M.); (S.S.); (D.L.); (K.M.S.); (K.S.); (K.L.); (D.R.); (E.-J.M.S.); (V.W.); (F.K.); (I.S.)
| | - Ernst-Jan M. Speel
- Department of Pathology, GROW-Research Institute for Oncology & Reproduction, Maastricht University, Medical Centre+, 6229 HX Maastricht, The Netherlands; (G.M.); (S.S.); (D.L.); (K.M.S.); (K.S.); (K.L.); (D.R.); (E.-J.M.S.); (V.W.); (F.K.); (I.S.)
| | - Véronique Winnepenninckx
- Department of Pathology, GROW-Research Institute for Oncology & Reproduction, Maastricht University, Medical Centre+, 6229 HX Maastricht, The Netherlands; (G.M.); (S.S.); (D.L.); (K.M.S.); (K.S.); (K.L.); (D.R.); (E.-J.M.S.); (V.W.); (F.K.); (I.S.)
| | - Faisal Klufah
- Department of Pathology, GROW-Research Institute for Oncology & Reproduction, Maastricht University, Medical Centre+, 6229 HX Maastricht, The Netherlands; (G.M.); (S.S.); (D.L.); (K.M.S.); (K.S.); (K.L.); (D.R.); (E.-J.M.S.); (V.W.); (F.K.); (I.S.)
- Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Al-Baha University, Albaha 65525, Saudi Arabia
| | - Iryna Samarska
- Department of Pathology, GROW-Research Institute for Oncology & Reproduction, Maastricht University, Medical Centre+, 6229 HX Maastricht, The Netherlands; (G.M.); (S.S.); (D.L.); (K.M.S.); (K.S.); (K.L.); (D.R.); (E.-J.M.S.); (V.W.); (F.K.); (I.S.)
| | - Axel zur Hausen
- Department of Pathology, GROW-Research Institute for Oncology & Reproduction, Maastricht University, Medical Centre+, 6229 HX Maastricht, The Netherlands; (G.M.); (S.S.); (D.L.); (K.M.S.); (K.S.); (K.L.); (D.R.); (E.-J.M.S.); (V.W.); (F.K.); (I.S.)
| |
Collapse
|
|
4
|
Manole B, Damian C, Giusca SE, Caruntu ID, Porumb-Andrese E, Lunca C, Dorneanu OS, Iancu LS, Ursu RG. The Influence of Oncogenic Viruses in Renal Carcinogenesis: Pros and Cons. Pathogens 2022; 11:757. [PMID: 35890003 PMCID: PMC9319782 DOI: 10.3390/pathogens11070757] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2022] [Revised: 06/29/2022] [Accepted: 06/30/2022] [Indexed: 02/05/2023] Open
Abstract
Viral infections are major contributors to the global cancer burden. Recent advances have revealed that known oncogenic viruses promote carcinogenesis through shared host cell targets and pathways. The aim of this review is to point out the connection between several oncogenic viruses from the Polyomaviridae, Herpesviridae and Flaviviridae families and renal carcinogenesis, highlighting their involvement in the carcinogenic mechanism. We performed a systematic search of the PubMed and EMBASE databases, which was carried out for all the published studies on RCC in the last 10 years, using the following search algorithm: renal cell carcinoma (RCC) and urothelial carcinoma, and oncogenic viruses (BKPyV, EBV, HCV, HPV and Kaposi Sarcoma Virus), RCC and biomarkers, immunohistochemistry (IHC). Our analysis included studies that were published in English from the 1st of January 2012 to the 1st of May 2022 and that described and analyzed the assays used for the detection of oncogenic viruses in RCC and urothelial carcinoma. The virus most frequently associated with RCC was BKPyV. This review of the literature will help to understand the pathogenic mechanism of the main type of renal malignancy and whether the viral etiology can be confirmed, at a minimum, as a co-factor. In consequence, these data can contribute to the development of new therapeutic strategies. A virus-induced tumor could be efficiently prevented by vaccination or treatment with oncolytic viral therapy and/or by targeted therapy.
Collapse
Affiliation(s)
- Bianca Manole
- Department of Morphofunctional Sciences I-Histolgy, Pathology, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania; (B.M.); (S.-E.G.); (I.D.C.)
| | - Costin Damian
- Department of Microbiology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania; (O.S.D.); (L.S.I.); (R.G.U.)
| | - Simona-Eliza Giusca
- Department of Morphofunctional Sciences I-Histolgy, Pathology, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania; (B.M.); (S.-E.G.); (I.D.C.)
| | - Irina Draga Caruntu
- Department of Morphofunctional Sciences I-Histolgy, Pathology, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania; (B.M.); (S.-E.G.); (I.D.C.)
| | - Elena Porumb-Andrese
- Department of Dermatology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania;
| | - Catalina Lunca
- Department of Microbiology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania; (O.S.D.); (L.S.I.); (R.G.U.)
| | - Olivia Simona Dorneanu
- Department of Microbiology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania; (O.S.D.); (L.S.I.); (R.G.U.)
| | - Luminita Smaranda Iancu
- Department of Microbiology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania; (O.S.D.); (L.S.I.); (R.G.U.)
| | - Ramona Gabriela Ursu
- Department of Microbiology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania; (O.S.D.); (L.S.I.); (R.G.U.)
| |
Collapse
|